Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.
about
Peptide-Based Treatment: A Promising Cancer TherapyEpidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesA systematic comparison of copy number alterations in four types of female cancerTEX101, a glycoprotein essential for sperm fertility, is required for stable expression of Ly6k on testicular germ cells.MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study.ING proteins as potential anticancer drug targets.UHRF1 is a novel diagnostic marker of lung cancer.HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers.Characterization and function of human Ly-6/uPAR molecules.Identification of immunogenic LY6K long peptide encompassing both CD4(+) and CD8(+) T-cell epitopes and eliciting CD4(+) T-cell immunity in patients with malignant diseaseTrial Watch: Peptide-based anticancer vaccines.The present status and future prospects of peptide-based cancer vaccines.Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer.Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancerAcute lymphoid leukemia cells with greater stem cell antigen-1 (Ly6a/Sca-1) expression exhibit higher levels of metalloproteinase activity and are more aggressive in vivo.Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS)Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.Genome-wide expression and copy number analysis identifies driver genes in gingivobuccal cancersTranscriptomic profiles differentiate normal rectal epithelium and adenocarcinoma.Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.The regulatory mechanism of the LY6K gene expression in human breast cancer cellsMultiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancerLy6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance.Epigenetic activation of LY6K predicts the presence of metastasis and poor prognosis in breast carcinoma.A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses.Molecular alterations and clinical relevance in esophageal squamous cell carcinoma.Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis.ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW.Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B.Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling.Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma.Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine.Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma.Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets.Identification of TNM stage-specific genes in lung adenocarcinoma by genome-wide expression profiling.Trial Watch: Peptide vaccines in cancer therapy.A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS.Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer.
P2860
Q26777032-65F25FAD-A446-4C3A-9C92-60526576E5F1Q27023830-454A5148-68DC-4DB2-8F2B-CF90CC39D0E9Q28394747-4B9DA796-E16C-48E0-ABCA-BFC23CB06DDDQ33289334-9F88AE2E-92AB-47CA-BB03-38015E7BA4DBQ33555885-895B56E7-1E96-4A4B-B5D6-01D726C206C5Q33574029-8DD2D188-4947-4C71-90E3-4FA6041665CCQ34005854-90D609CE-FE3B-46D4-A294-6A5E26B90698Q34292197-8EAFDD0B-CF4C-4A7D-BA31-20DF08CDC3C4Q34314038-D30F13CA-1BD1-4FDD-B6E1-541516BF12D5Q34372937-5B75FFDA-7593-4642-875C-20F32E682BD2Q34483345-05A42D78-C607-426B-A9CA-196897217180Q34528638-C7386E88-2DB3-4BD8-8336-20F4ABE427BDQ34627201-EF5DF8F1-3455-4D46-B61F-79041051B7C2Q35074445-5CF2148E-EBF3-4C03-91F1-28C9072B3571Q35106493-2224D93C-7463-4A52-8905-1E8776E326F3Q35201830-BF28E5CD-83D3-4B78-8CC1-07A6C96BB6BCQ35444274-608B6C52-8664-48AC-9277-95C412A9348CQ35569528-74457B41-5515-4673-922C-F1F113867BBFQ35600924-87EAB85D-EF1E-4CF1-BC47-824D2D36364DQ35676166-713D888F-D133-42D9-8CE7-4FA75F91EFB2Q36112645-75C6B265-BB29-4CB1-A6EC-46DD9E2F7182Q36385900-D2390858-61F0-463D-8F1B-1401660333ADQ36803441-87969322-F8B6-47D6-A592-532430067FCDQ37012226-88537040-0F9F-4F1A-9CE8-4F131ECE7958Q37688300-C0629CA7-2AC4-41C4-B52F-4F01FC29B443Q38105238-7FB5FC32-F905-409C-9F52-3613303802BEQ38134029-BF54A40D-45C9-4C3E-8928-6C21003BDC68Q38406799-68352C19-6701-423B-BB52-516DE080D3FDQ38541959-25764480-6CE1-4FBE-BDD8-D69F4B03151BQ39275975-C2662327-B57E-45F5-8A28-E9C645D80ACCQ39335373-18F7ED00-EB21-4AE0-8A59-F6C243FF6214Q39633864-1F9DB4C1-9B52-4591-8F75-3DC70E844873Q39985993-62D9A4E8-84E7-4B1C-8E3C-8B94EFFFD4ACQ40978230-82AF1DF9-6521-408F-B517-4A8EBEC3890DQ40981383-1D31C853-B42F-406F-8012-EE9E8A96A1CFQ41460801-7C9672E0-51BD-4DE8-B8A9-AEB435D69B8CQ42108679-7F0AECCF-6E1D-4364-AFCB-96B349AD5148Q42734544-0B73DBBD-9D7E-4CC6-BC40-52A73E006E52Q43245237-C1345679-6CC2-43E7-91E6-2A06BAE18109Q51047134-918B5278-9988-468F-BAAF-96CD83CC322D
P2860
Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cancer-testis antigen lymphocy ...... ung and esophageal carcinomas.
@en
type
label
Cancer-testis antigen lymphocy ...... ung and esophageal carcinomas.
@en
prefLabel
Cancer-testis antigen lymphocy ...... ung and esophageal carcinomas.
@en
P2093
P1433
P1476
Cancer-testis antigen lymphocy ...... ung and esophageal carcinomas.
@en
P2093
Atsushi Takano
Eiju Tsuchiya
Haruhiko Nakayama
Hiroyuki Ito
Hitoshi Nishimura
Kouki Inai
Masahiro Fujita
Masao Hosokawa
Nobuhisa Ishikawa
Nobuoki Kohno
P304
11601-11611
P356
10.1158/0008-5472.CAN-07-3243
P407
P577
2007-12-01T00:00:00Z